Could CAR t-cells tame autoimmune disease? new trial launches.

NCT ID NCT06680037

First seen Oct 31, 2025 · Last updated May 20, 2026 · Updated 28 times

Summary

This early-phase study tests a new treatment called azercabtagene zapreleucel (azer-cel) for people with B-cell mediated autoimmune disorders like multiple sclerosis. About 100 adults will receive this cell therapy to find the safest dose and see if it can control disease activity. The goal is to manage the condition, not cure it, as ongoing treatment may still be needed.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-CELL MEDIATED AUTOIMMUNE DISORDERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • TG Therapeutics Investigational Trial Site

    RECRUITING

    La Jolla, California, 92093, United States

  • TG Therapeutics Investigational Trial Site

    RECRUITING

    Ann Arbor, Michigan, 48019, United States

  • TG Therapeutics Investigational Trial Site

    RECRUITING

    Omaha, Nebraska, 68198, United States

  • TG Therapeutics Investigational Trial Site

    RECRUITING

    New York, New York, 10025, United States

  • TG Therapeutics Investigational Trial Site

    RECRUITING

    Rochester, New York, 14642, United States

  • TG Therapeutics Investigational Trial Site

    RECRUITING

    Cleveland, Ohio, 44195, United States

  • TG Therapeutics Investigational Trial Site

    RECRUITING

    Columbus, Ohio, 43210, United States

  • TG Therapeutics Investigational Trial Site

    RECRUITING

    Milwaukee, Wisconsin, 53226, United States

Conditions

Explore the condition pages connected to this study.